Product: CARDAMYST® (etripamil) Nasal Spray

Company: Milestone Pharmaceuticals

About the Product:

CARDAMYST® (etripamil) nasal spray is the first and only FDA-approved, self-administered treatment for the rapid conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. This novel calcium channel blocker is uniquely paired with an intranasal delivery system enabling patients to treat attacks wherever they occur. CARDAMYST provides healthcare professionals with a safe and rapid-acting treatment approach that supports a patients' ability to self-administer a treatment for this serious cardiovascular disease. Currently, etripamil is in Phase 3 development for control of acute AFib-RVR in adults. For more information, visit CARDAMYST.com.

Product: VAFSEO® (vadadustat)

Company: Akebia Therapeutics

About the Product:

Product: SPRAVATO® Nasal Spray

Company: Johnson & Johnson Innovative Medicine

About the Product:

Product: VOQUEZNA®

Company: Phathom Pharmaceuticals

About the Product:

VOQUEZNA (vonoprazan) is a first-in-class potassium-competitive acid blocker (PCAB) approved in the U.S. for the treatment of gastroesophageal reflux disease (GERD) and, in combination with antibiotics, for H. pylori infection. With a novel mechanism of action, VOQUEZNA delivers rapid, potent, and durable acid suppression, with a safety profile comparable to proton pump inhibitors (PPIs). In pivotal Phase 3 trials, VOQUEZNA demonstrated key efficacy advantages over a PPI across multiple endpoints. Its approval represents the first major innovation in GERD treatment in more than 30 years, offering the potential to significantly advance care for millions of patients with acid-related disorders.

Product: HERNEXEOS® (zongertinib tablets)

Company: Boehringer Ingelheim

About the Product:

HERNEXEOS® (zongertinib tablets) is an irreversible tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 (ERBB2) and the first orally administered, targeted therapy for adult patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer. With HERNEXEOS, Boehringer Ingelheim is delivering on the promise to transform care for people with this rare and aggressive cancer. HERNEXEOS is also being evaluated across a range of earlier stages and advanced solid tumors with HER2 alterations. Boehringer has a clear aspiration - to transform the lives of people facing cancer by delivering unprecedented impact, with the ultimate goal to redefine standards of care.

Product: TALVEY® (talquetamab-tgvs)

Company: UroGen Pharma

About the Product:

ZUSDURI® is the first and only FDA-approved non-surgical medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). [JK1.1]Combining mitomycin with UroGen's proprietary reverse thermal hydrogel (RTGel®) technology, ZUSDURI is an intravesical chemoablative therapy that provides potent tumor ablation through, prolonged drug dwell time. Unlike the traditional management of recurrent LG-IR-NMIBC, which relies on repeated transurethral resection of bladder tumors (TURBT), ZUSDURI offers a non-surgical pharmacologic treatment option that can be administered in an ambulatory setting. In the pivotal ENVISION trial, 78% of response-evaluable patients achieved a complete response, with 79% of responders remaining in complete response for at least 12 months. ZUSDURI represents an important advancement by providing an effective non-surgical treatment option for patients with recurrent LG-IR-NMIBC.

Product: TRYPTYR® (acoltremon ophthalmic solution)

Company: Alcon

About the Product:

TRYPTYR is the first topical ocular pharmaceutical neuromodulator that leverages the eye's natural mechanism for regulating tear production to replenish basal tears. It stimulates TRPM8 receptors, activating the trigeminal nerve to coordinate secretion from the lacrimal glands, meibomian glands, and goblet cells to replenish the body’s natural tears. Unlike traditional Dry Eye Disease treatments that primarily supplement tears or target inflammation, TRYPTYR increases the neurosensory drive to produce basal tears and has been shown to increase natural tear production as early as Day 1. This innovative approach offers patients and clinicians a faster, evidence-based option for managing Dry Eye Disease.